Request Demo

Last update 08 May 2025

El Centro de Investigación Biomédica en Red

Private Company|Spain

Last update 08 May 2025

Overview

Pipeline

Deal

Translational Medicine

Overview

Clinical Trials associated with El Centro de Investigación Biomédica en Red

NCT06533852

/ Not yet recruitingPhase 3IIT

Fecal Microbiome Transplantation in Cirrhosis: Randomized, Double-blinded, Placebo-Controlled Trial in Patients With Decompensated Cirrhosis

This is a phase III, multicenter, double-blind, placebo-controlled, randomized clinical trial to evaluate the safety and efficacy of Fecal Microbiota Transplantation (FMT) from healthy subjects to patients with decompensated cirrhosis.

Start Date01 Dec 2024

Sponsor / Collaborator

El Centro de Investigación Biomédica en Red

ISRCTN14236593

/ RecruitingNot ApplicableIIT

Effect of mandarin orange consumption on omics biomarkers and cardiometabolic phenotypes: A Randomized clinical trial in the general population (MANSomics)

Start Date15 Nov 2024

Sponsor / Collaborator

University of Valencia

[+1]

NCT05653726

/ RecruitingNot ApplicableIIT

Impact of Noninvasive Telemonitoring on Clinical Events, Healthcare Resource Use and Costs in Heart Failure

The goal of this clinical trial is to know if telemonitoring and telematic follow-up reduces the healthcare resources utilization, healthcare costs and non-healthcare costs of patients with high-risk heart failure. The main questions it aims to answer are:
* Does telematic follow-up reduce de use of healthcare resource utilization of patients with heart failure?
* Is telematic follow-up cost-efficient in terms of reducing direct healthcare costs in heart failure patients?
* Is telematic follow-up cost-efficient in terms of reducing non-healthcare costs in heart failure patients? Participants will be randomized to usual care (control group) or telematic care (interventional group). Patients randomized to the interventional group will be included in a protocol of daily automatic telemonitoring of arterial pressure, peripheral oximetry, heart rate and weight, and telematic consultations lead by a heart failure clinical specialized team.
Researchers will compare the healthcare resource utilization, healthcare and non-healthcare costs of patients randomized to control vs. interventional group.

Start Date29 Nov 2023

Sponsor / Collaborator

El Centro de Investigación Biomédica en Red

100 Clinical Results associated with El Centro de Investigación Biomédica en Red

0 Patents (Medical) associated with El Centro de Investigación Biomédica en Red

Literatures (Medical) associated with El Centro de Investigación Biomédica en Red

01 Jun 2025·Bioorganic Chemistry

Amoebicidal thymol analogues against brain-eating amoeba, Naegleria fowleri

Article

Author: Lorenzo-Morales, Jacob ; Sifaoui, Ines ; Bazzocchi, Isabel L ; Piñero, José E ; Sebai, Hichem ; Chao-Pellicer, Javier ; Omrani, Amani ; Jimenez, Ignacio A ; Ben Youssef, Meriam ; Hernández-Álvarez, Eduardo

Naegleria fowleri, known as the brain-eating amoeba, is the pathogen parasite that causes primary amoebic meningoencephalitis. None of the currently available therapies are fully effective, mainly due to the inefficacy of pharmacotherapy. In this regard, natural products and related compounds represent a promising strategy for amoebicidal drug discovery. Herein, a series of eight monoterpene phenol derivatives of thymol bearing ester, carbonate, or carbamate moieties were prepared, and screened as potential amoebicidal agents on N. fowleri. The cytotoxicity of these compounds on murine macrophages cell line J774 was also evaluated to assess their selectivity. Compounds 3, 4, 7 and 8 showed significant activity against the N. fowleri trophozoite. Moreover, 4-nitrophenyl thymyl carbonate 8 displayed the highest potency, showing IC₅₀ values of 22.87 and 25.16 μM against N. fowleri trophozoite and cyst stages, respectively, coupled with low cytotoxicity on a mammal cell line. Furthermore, mechanism of action studies revealed that derivative 8 triggered programmed cell death via cytosolic calcium accumulation, mitochondrial alteration, membrane damage, chromatin condensation, and ROS accumulation. In addition, the in-silico ADME analysis indicated that derivative 8 exhibits exceptional drug-likeness meeting all the pharmacokinetic criteria. These results highlight derivative 8 as a promising amoebicidal agent to develop new drugs for the treatment of Naegleria infections.

01 Apr 2025·Journal of Patient Safety

Automated Computerized-based Intervention to Identify Hypomagnesemia in Primary Care Patients With Arrhythmia

Article

Author: Flores, Emilio ; Ahumada, Miguel ; Leiva-Salinas, Carlos ; Blasco, Alvaro ; López-Garrigós, Maite ; Leiva-Salinas, María

Objectives:Hypomagnesemia early diagnosis and consequently early, timely magnesium supplementation is of utmost benefit, but it often goes underdiagnosed. The objective was to show and monitor an intervention to identify hypomagnesemia in patients with arrhythmia.Methods:A cross-sectional study was designed in the laboratory. In primary care patients, the Laboratory Information System would automatically add a serum magnesium test when sample availability is present in any request when a diagnosis of arrhythmia is made. We counted the number of detected patients with hypomagnesemia (serum magnesium <1.7 mg/dL, <0.7 mmol/L), and calculated the cost in reagent of each identified case.Results:In 430 patients with arrhythmia, serum magnesium was measured, and 41 (9.5%) had hypomagnesemia results. One patient showed severe hypomagnesemia values (<1.2 mg/dL and <0.49 mmol/L). Patients with a deficit were significantly (P<0.01) older than the total group of patients with normal magnesium values (66.3±13.2 versus 61.6±12.5). Each case represented a cost of 3.15€ in reagent.Conclusions:The automated computer-based intervention to identify patients with hypomagnesemia was useful and affordable, given the cost per detected case.

01 Feb 2025·Nutrition

Parent–child microbiota relationships involved in childhood obesity: A CORALS ancillary study

Article

Author: Salas-Salvadó, Jordi ; Gil-Campos, Mercedes ; de Cuevillas, Begoña ; Pastor-Villaescusa, Belén ; Navas-Carretero, Santiago ; Leis, Rosaura ; Moreno, Luis A ; De Miguel-Etayo, Pilar ; Galera Alquegui, Sergio ; Riezu-Boj, Jose I. ; Martínez, J. Alfredo ; Milagro, Fermín I. ; Babio, Nancy ; Milagro, Fermín I ; Moreno, Luis A. ; Alquegui, Sergio Galera ; Riezu-Boj, Jose I ; Martínez, J Alfredo

OBJECTIVESChildhood obesity continues to rise worldwide. Family gut microorganisms may be associated with childhood obesity. The aim of the study was to analyze bacterial similarities in fecal microbiota composition between parent-offspring pairs as linked to body weight.METHODSA total of 146 father/mother and offspring pairs were categorized into four groups according to the weight status of the parent-child pair as follows: group 1, parent and child with normal weight; group 2, parent and child with overweight/obesity; group 3, parent with normal weight and child with overweight/obesity; group 4, parent with overweight/obesity and child with normal weight. Anthropometric measurements and lifestyle assessments were performed in all participants. Microbiota characteristics were determined by 16S ribosomal RNA gene sequencing. Logistic regression models were performed to determine whether the abundance of any bacteria was able to predict childhood obesity. Moreover, receiver operating characteristic curves were fitted to define the relative diagnostic strength of bacterial taxa for the correct identification of childhood obesity.RESULTSThe absence/abundance of Catenibacterium mitsuokai, Prevotella stercorea, Desulfovibrio piger, Massiliprevotella massiliensis, and Phascolarctobacterium succinatutens was involved in body weight family associations. A positive relationship between P. succinatutens richness from parents and M. massiliensis from children was observed with regard to body weight status (odds ratio, 1.14, P = 0.013).CONCLUSIONSThis study describes five potential gut bacteria that may be putatively involved in family weight status relationships and appear to be useful for predicting obesity.

100 Deals associated with El Centro de Investigación Biomédica en Red

100 Translational Medicine associated with El Centro de Investigación Biomédica en Red

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 17 Dec 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

El Centro de Investigación Biomédica en Red

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 17 Dec 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing